Effects of budesonide/formoterol combination therapy versus budesonide alone on airway dimensions in asthma

Respirology

Volumn 17, Issue 4, 2012, Pages 639-646

  Hoshino, Makoto ^a   Ohtawa, Junichi ^a  

^a International University of Health and Welfare   (Japan)

Author keywords

airway inflammation; airway wall thickness; asthma; budesonide; formoterol

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL;

ADULT; AIRWAY; ARTICLE; ASTHMA; BODY SURFACE; BRONCHUS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; EMOTION; ENVIRONMENT; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LUNG FUNCTION; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SPUTUM EXAMINATION; TREATMENT DURATION;

EID: 84859916942     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02130.x     Document Type: Article

References (42)

1. Bousquet J, Jeffery PK, Busse WW, et al,. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med. 2000; 161: 1720-45. (Pubitemid 30329053)
2. Little SA, Sproule MW, Cowan MD, et al,. High resolution computed tomographic assessment of airway wall thickness in chronic asthma: reproducibility and relationship with lung function and severity. Thorax 2002; 57: 247-53. (Pubitemid 34214412)
3. Awadh N, Müller NL, Park CS, et al,. Airway wall thickness in patients with near fatal asthma and control groups: assessment with high resolution computed tomographic scanning. Thorax 1998; 53: 248-53. (Pubitemid 28215782)
4. Niimi A, Matsumoto H, Amitani R, et al,. Airway wall thickness in asthma assessed by computed tomography. Relation to clinical indices. Am. J. Respir. Crit. Care Med. 2000; 162: 1518-23.
5. Kasahara K, Shiba K, Ozawa T, et al,. Correlation between the bronchial subepithelial layer and whole airway wall thickness in patients with asthma. Thorax 2002; 57: 242-6. (Pubitemid 34214411)
6. Greening AP, Ind PW, Northfield M, et al,. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-24. (Pubitemid 24229008)
7. Woolcock A, Lundback B, Ringdal N, et al,. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 1996; 153: 1481-8. (Pubitemid 26141329)
8. Pauwels RA, Löfdahl CG, Postma DS, et al,. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 1997; 337: 1405-11.
9. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J. Allergy Clin. Immunol. 2007; 120 (Suppl.): S94-138.
10. Zetterström O, Buhl R, Mellem H, et al,. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur. Respir. J. 2001; 18: 262-8. (Pubitemid 32776399)
11. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al,. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am. J. Respir. Crit. Care Med. 2001; 164: 1392-7. (Pubitemid 33124016)
12. Kelly MM, O'Connor TM, Leigh R, et al,. Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma. J. Allergy Clin. Immunol. 2010; 125: 349-56.
13. Whelan CJ, Johnson M, Vardey CJ,. Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung. Br. J. Pharmacol. 1993; 110: 613-18. (Pubitemid 23279268)
14. Li X, Ward C, Thien F, et al,. An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am. J. Respir. Crit. Care Med. 1999; 160: 1493-9.
15. Anderson GP,. Interactions between corticosteroids and β-adrenergic agonists in asthma disease induction, progression, and exacerbation. Am. J. Respir. Crit. Care Med. 2000; 161: S188-96.
16. Nakano Y, Muro S, Sakai H, et al,. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am. J. Respir. Crit. Care Med. 2000; 162: 1102-8.
17. Matsuoka S, Kurihara Y, Yagihashi K, et al,. Airway dimensions on inspiratory and expiratory multisection CT in chronic obstructive pulmonary disease: correlation with airflow limitation. Radiology 2008; 248: 1042-9.
18. Okazawa M, Müller N, McNamara AE, et al,. Human airway narrowing measured using high resolution computed tomography. Am. J. Respir. Crit. Care Med. 1996; 154: 1557-62. (Pubitemid 26391213)
19. Pin I, Gibson PG, Kolendowicz R, et al,. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47: 25-9.
20. Hoshino M, Handa H, Miyazawa T,. Effects of salmeterol and fluticasone propionate combination versus fluticasone propionate on airway function and eosinophilic inflammation in mild asthma. Allergol. Int. 2009; 58: 357-63.
21. Cockcroft DW, Killian DN, Mellon JJ, et al,. Bronchial reactivity to inhaled histamine; a method and clinical survey. Clin. Allergy 1977; 7: 235-43. (Pubitemid 8159924)
22. Juniper EF, Guyatt GH, Epstein RS, et al,. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76-83.
23. Bateman ED, Bantje TA, João Gomes M, et al,. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am. J. Respir. Med. 2003; 2: 275-81. (Pubitemid 36869441)
24. Jenkins C, Kolarikova R, Kuna P, et al,. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology 2006; 11: 276-86.
25. Roth M, Johnson PR, Rüdiger JJ, et al,. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360: 1293-9. (Pubitemid 35284621)
26. Hadcock JR, Wang HY, Malbon CC,. Agonist-induced destabilization of beta-adrenergic receptor mRNA. Attenuation of glucocorticoid-induced up-regulation of beta-adrenergic receptors. J. Biol. Chem. 1989; 264: 19928-33. (Pubitemid 20008107)
27. Mak JC, Nishikawa M, Shirasaki H, et al,. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J. Clin. Invest. 1995; 96: 99-106.
28. Adcock IM, Maneechotesuwan K, Usmani O,. Molecular interactions between glucocorticoids and long-acting beta2-agonists. J. Allergy Clin. Immunol. 2002; 110: S261-8. (Pubitemid 35471714)
29. Eickelberg O, Roth M, Lörx R, et al,. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem. 1999; 274: 1005-10.
30. Usmani OS, Ito K, Maneechotesuwan K, et al,. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am. J. Respir. Crit. Care Med. 2005; 172: 704-12. (Pubitemid 41324225)
31. Johnson M,. Effects of beta2-agonists on resident and infiltrating inflammatory cells. J. Allergy Clin. Immunol. 2002; 110: S282-90. (Pubitemid 35471717)
32. Kaur M, Chivers JE, Giembycz MA, et al,. Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol. Pharmacol. 2008; 73: 203-14. (Pubitemid 350294211)
33. Ward C, Johns DP, Bish R, et al,. Reduced airway distensibility, fixed airflow limitation, and airway wall remodeling in asthma. Am. J. Respir. Crit. Care Med. 2001; 164: 1718-21. (Pubitemid 33124164)
34. Minshall EM, Leung DY, Martin RJ, et al,. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am. J. Respir. Cell Mol. Biol. 1997; 17: 326-33. (Pubitemid 127500837)
35. Vignola AM, Chanez P, Chiappara G, et al,. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am. J. Respir. Crit. Care Med. 1997; 156: 591-9. (Pubitemid 27352000)
36. Todorova L, Gürcan E, Westergren-Thorsson G, et al,. Budesonide/formoterol effects on metalloproteolytic balance in TGFbeta-activated human lung fibroblasts. Respir. Med. 2009; 103: 1755-63.
37. Hoshino M, Takahashi M, Aoike N,. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J. Allergy Clin. Immunol. 2001; 107: 295-301. (Pubitemid 32173907)
38. Wang K, Liu CT, Wu YH, et al,. Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within airway remodelling in asthma. Adv. Ther. 2008; 25: 342-54.
39. Niimi A, Matsumoto H, Amitani R, et al,. Effect of short-term treatment with inhaled corticosteroid on airway wall thickening in asthma. Am. J. Med. 2004; 116: 725-31. (Pubitemid 38622308)
40. Giembycz MA, Kaur M, Leigh R, et al,. A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br. J. Pharmacol. 2008; 153: 1090-104. (Pubitemid 351415494)
41. Duong M, Gauvreau G, Watson R, et al,. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J. Allergy Clin. Immunol. 2007; 119: 322-7. (Pubitemid 46210078)
42. Aysola RS, Hoffman EA, Gierada D, et al,. Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest 2008; 134: 1183-91.